Scholar Rock Holding Corp. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on October 19, 2020, regarding events occurring on October 16, 2020. Scholar Rock Holding Corporation, a biopharmaceutical company, entered into a material definitive agreement to secure financing for its operations and clinical development programs.
Key Financial Metrics and Transaction Details
The filing details a new term loan facility rather than historical financial performance metrics such as revenue or profit.
- Total Facility Size: Up to $50.0 million in aggregate principal.
- Initial Funding (Tranche 1): $25.0 million received on the closing date.
- Contingent Funding (Tranche 2): Up to $25.0 million available by December 31, 2021, subject to clinical milestones.
- Interest Rate: The greater of (i) WSJ Prime Rate + 4.60% or (ii) 7.85% per annum.
- Final Payment Fee: 4.00% of the original principal amount advanced.
- Maturity Date: May 1, 2025.
- Amortization: Interest-only payments until December 1, 2022, followed by 30 equal monthly installments.
- Prepayment Fees: 3.00% if prepaid within the first year; 2.00% if prepaid in the second year; no fee thereafter.
Material Changes and Milestones
The primary material change is the addition of $25.0 million in immediate debt financing. The potential for an additional $25.0 million is contingent upon the achievement of specific clinical milestones by December 31, 2021:
- Dosing the first patient in a Phase 3 clinical trial for SRK-015.
- Dosing the first patient in Part B of the DRAGON Phase 1 clinical trial for SRK-181.
The loan is secured by a senior security interest in substantially all of the Borrower's assets, excluding intellectual property.
Outlook, Risks, and Covenants
Management intends to use the proceeds for working capital and general corporate purposes. The agreement includes customary covenants limiting additional indebtedness, liens, mergers, and asset sales. Events of default include non-payment, covenant breaches, insolvency, and material adverse effects. The filing notes that the full agreement will be filed as an exhibit to the Form 10-K for the year ending December 31, 2020.
Key Facts for Investor Verification
- Verify the current status of the Phase 3 trial for SRK-015 and the DRAGON Phase 1 trial for SRK-181 to assess the likelihood of securing Tranche 2 funding.
- Confirm the total outstanding debt load of the company post-closing to evaluate leverage ratios.
- Review the specific "limited exceptions" regarding the security interest to understand which assets remain unencumbered.
- Monitor the company's cash burn rate to ensure sufficient liquidity to cover interest-only payments through December 2022.